Bio-Rad Laboratories Inc. Class A Common Stock (NYSE:BIO)

Home >> Stock >> Bio-Rad Laboratories Inc. Class A Common Stock >> Metrics

Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories....

+See More
See More

Blog+More

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Apple Boston

2023-03-14 16:43:00 Tuesday ET

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes.

Several feasible near-term reforms can substantially narrow the scope for global tax avoidance by closing information loopholes. Thomas Pogge and Krishen

+See More

AYA Analytica podcast provides fresh insights into the latest stock market news, economic trends, and investment portfolio strategies.

Andy Yeh Alpha

2019-02-28 20:44:00 Thursday ET

AYA Analytica podcast provides fresh insights into the latest stock market news, economic trends, and investment portfolio strategies.

AYA Analytica finbuzz podcast channel on YouTube February 2019 In this podcast, we discuss several topical issues as of February 2019: (1) our proprieta

+See More

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Laura Hermes

2025-05-29 08:25:28 Thursday ET

Ben Horowitz shares many hard truths, setbacks, failures, obstacles, difficulties, and disappointments through his rare unique entrepreneurial journey at LoudCloud.

Serial venture capitalist Ben Horowitz describes many hard truths, lessons, and insights from his entrepreneurial journey of running LoudCloud from a Silico

+See More

Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor.

Apple Boston

2018-08-11 14:35:00 Saturday ET

Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor.

The Trump administration imposes 20%-50% tariffs on Turkish imports due to a recent spat over the detention of an American pastor, Andrew Brunson, in Turkey

+See More

Business titans often step away from their urgent work, slow down, and invest in self-enrichment.

Laura Hermes

2017-12-23 10:40:00 Saturday ET

Business titans often step away from their urgent work, slow down, and invest in self-enrichment.

Despite having way more responsibility than anyone else, top business titans such as Warren Buffett, Charlie Munger, and Oprah Winfrey often step away from

+See More

The Trump $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike.

Joseph Corr

2018-03-15 07:41:00 Thursday ET

The Trump $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike.

The Trump administration's $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike

+See More